Questions
Ipamorelin: the questions people actually ask
Direct, cited answers on the CJC-1295 stack, effects, half-life, regulatory status, and the limits of the evidence.
What does CJC-1295 and ipamorelin do?
Together they aim to raise growth hormone through two complementary routes — ipamorelin pulses GH via the ghrelin receptor, CJC-1295 sustains it via the GHRH receptor. CJC-1295 alone produced 2- to 10-fold GH increases for 6+ days and 1.5- to 3-fold IGF-1 elevation in healthy adults [7]. The combination itself has never been tested in a controlled trial.
How much CJC-1295 ipamorelin should I take?
There is no evidence-based dose, and this site won't invent one. No controlled human trial has tested the CJC-1295 + ipamorelin combination for any outcome, so any figure online is extrapolated from single-agent pharmacology, not data [3][7]. The only human ipamorelin dosing in the literature is an intravenous research regimen [2], which is not a self-administration guide.
Does CJC-1295 ipamorelin work?
Each peptide moves GH on its own; the combination is untested. CJC-1295 reliably raised GH and IGF-1 in healthy adults [7], and ipamorelin pulses GH in animals and humans [1][2] — but ipamorelin failed its one human efficacy trial [3], and no trial has evaluated the actual stack for a defined outcome. "Works" depends entirely on what outcome you mean.
Where to inject CJC-1295 ipamorelin?
In community use the route is subcutaneous, but that route has no published human safety or pharmacokinetic characterization for ipamorelin [2]. The favorable efficacy data in the literature come from intravenous (human and rodent) and intraperitoneal (rodent) dosing, not subcutaneous self-injection. This site reports routes studied in research and does not give injection instructions.
Can you take CJC-1295 ipamorelin and sermorelin together?
There is no trial evidence for combining all three. CJC-1295 and sermorelin are both GHRH analogs acting on the same receptor, so stacking two GHRH analogs is mechanistically redundant rather than additive, while ipamorelin works through the separate ghrelin receptor [1]. No controlled study has tested any of these multi-peptide combinations for safety or efficacy.
Can you take tesamorelin and ipamorelin together?
Mechanistically they are complementary — tesamorelin is a GHRH analog, ipamorelin a ghrelin-receptor agonist, the same GHRH-plus-GHRP logic behind the CJC-1295 pairing [1]. But no controlled trial has tested this combination, and tesamorelin is FDA-approved only for HIV-associated visceral fat, not for stacking [11]. The pairing rests on rationale, not combination data.
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the first highly selective growth hormone secretagogue. In its founding study it released GH potently in rat cells, rats, and swine (swine ED50 2.3 nmol/kg vs 3.9 for GHRP-6) without raising ACTH or cortisol even far above its GH threshold [1]. It is a research peptide, not an approved drug.
What does ipamorelin do for you?
Mechanistically it triggers a clean pulse of growth hormone via the ghrelin receptor, without the cortisol and prolactin spillover of older peptides [1]. In rodents that translated to longitudinal bone growth [4] and body-composition shifts [14]. In people, the one efficacy trial — for gut recovery after surgery — did not meet its endpoint [3], so human benefit claims remain unproven.
What is ipamorelin peptide?
It is a wholly synthetic five-amino-acid peptide, MW ~712 Da, CAS 170851-70-4, built by trimming a central dipeptide from the older peptide GHRP-1. Two D-form amino acids make it resist breakdown. It selectively activates GHS-R1a, the ghrelin / GH-secretagogue receptor, to release GH [1]. It is not a natural human peptide; it mimics ghrelin at that receptor.
What are the risks of ipamorelin?
The documented risk picture is mostly about unknowns. The one human trial showed no compound-specific safety signal over 7 days [3], but there is no long-term human data. Class-level concerns include a chronic cardiotoxicity signal from a related ghrelin-receptor agonist in rats [6] and the theoretical GH/IGF-1 cancer-promotion question [13]. Gray-market purity is unverified.
Does ipamorelin reduce belly fat?
Direct evidence is thin and indirect. In a 2024 ferret study, ipamorelin (1–3 mg/kg) reduced cisplatin-induced weight loss by ~24% — a weight-protective, not fat-burning, effect [5]. Rodent data show GH-dependent and GH-independent body-composition shifts [14], and community reports describe a slow lean-out, but no controlled human trial has tested ipamorelin for fat loss.
What are the downsides of ipamorelin?
On the data side: a failed human efficacy trial [3], no long-term human safety, a class-level cardiotoxicity signal in rats [6], and unverified research-grade purity. On the reported side: flushing, hunger, water retention, tingling, and injection-site irritation are commonly described (anecdotal). The marketing for anti-aging and fat loss far outpaces the controlled evidence.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved, marketed drug, so it isn't being "discontinued" in the usual sense. Its only clinical program — postoperative ileus — failed its Phase 2 endpoint and development stopped [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, restricting compounding-pharmacy access [11].
Does ipamorelin increase IGF-1?
Not reliably in short studies. In its founding characterization and in a 15-day rat bone-growth study, ipamorelin raised GH but did not change total IGF-1 [1][4]. Sustained protocols and the GHRH-analog partners (like CJC-1295, which raised IGF-1 1.5- to 3-fold [7]) are where durable IGF-1 elevation appears — which is part of why ipamorelin is paired with them.
How does CJC-1295 ipamorelin work?
Through two separate receptors. Ipamorelin activates GHS-R1a (the ghrelin receptor) for a short GH pulse; CJC-1295 activates the GHRH receptor for a sustained elevation [1]. The two pathways are synergistic, so the intended result is a larger, longer GH signal than either alone — though the combination has only ever been inferred from each agent's separate data [7][8].
How to reconstitute CJC-1295 ipamorelin 5mg?
This is a research-handling question, not a clinical instruction. Ipamorelin ships as a lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and freeze-thaw, so solution is kept refrigerated. A blended "5 mg" research vial is not a quality-assured pharmaceutical, and this site provides no reconstitution volumes or dosing math.
How long does ipamorelin stay in your system?
Not long. In healthy human volunteers the terminal half-life was approximately 2 hours, with clearance of 0.078 L/h/kg [2]. Practically, most of a dose is cleared within several hours, and the GH it triggers comes as a single pulse peaking about 40 minutes after dosing [2]. The short half-life is why it is described as a pulsing, short-acting secretagogue.
Does ipamorelin make you hungry?
It plausibly can. Ipamorelin acts on the ghrelin receptor, and ghrelin is the appetite-driving "hunger hormone"; central ghrelin-receptor activation switches on feeding circuits in animals [15]. Community reports describe an appetite bump after dosing, milder than with GHRP-6 but real. No controlled human appetite data exist at research-use doses.
Will I gain weight on ipamorelin?
Animal data say weight can go up. Ipamorelin produced a small (~15%) body-weight increase in both GH-deficient and GH-intact mice over two weeks, with raised fat-pad weight and leptin [14], and oral ipamorelin-derived analogs caused weight gain in rats [12]. Whether that means lean mass, fluid, or fat depends on context; no controlled human body-weight trial exists. Community reports also note transient water retention.
Does ipamorelin increase appetite?
Mechanistically yes, because it is a ghrelin-receptor agonist, and ghrelin drives appetite; central administration of ghrelin-receptor agonists induced feeding in animal studies [15]. The effect is reported by users as milder than GHRP-6 but present. A 2026 sports-medicine review classed ipamorelin as investigational with an uncertain profile [16], and there is no controlled human appetite measurement at research-use doses.
What does ipamorelin peptide do?
It triggers a selective pulse of growth hormone via the ghrelin receptor, without raising cortisol or prolactin [1] — that is its defining action. Downstream, GH supports tissue repair and metabolism; in rodents this showed up as bone growth [4] and altered body composition [14]. The one human efficacy trial it faced (gut recovery) did not work [3], so proven human benefits remain absent.
How long does it take for ipamorelin to work?
At the hormonal level, fast: the GH pulse peaks about 40 minutes after a dose, and the drug clears with a ~2-hour half-life [2]. At the level of subjective effects, community reports describe sleep changes within one to two weeks and slower body-composition shifts over weeks to months (anecdotal). No controlled human trial has measured an onset for these reported effects.